Suppr超能文献

恢复线粒体自噬可改善 Barth 综合征的心肌病。

Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome.

机构信息

Sam and Ann Barshop Institute for Longevity and Aging Studies, Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, People's Republic of China.

出版信息

Autophagy. 2022 Sep;18(9):2134-2149. doi: 10.1080/15548627.2021.2020979. Epub 2022 Jan 5.

Abstract

Barth syndrome (BTHS) is an X-linked genetic disorder caused by mutations in the gene which encodes a transacylase required for cardiolipin remodeling. Cardiolipin is a mitochondrial signature phospholipid that plays a pivotal role in maintaining mitochondrial membrane structure, respiration, mtDNA biogenesis, and mitophagy. Mutations in the gene deplete mature cardiolipin, leading to mitochondrial dysfunction, dilated cardiomyopathy, and premature death in BTHS patients. Currently, there is no effective treatment for this debilitating condition. In this study, we showed that TAFAZZIN deficiency caused hyperactivation of MTORC1 signaling and defective mitophagy, leading to accumulation of autophagic vacuoles and dysfunctional mitochondria in the heart of knockdown mice, a rodent model of BTHS. Consequently, treatment of TAFAZZIN knockdown mice with rapamycin, a potent inhibitor of MTORC1, not only restored mitophagy, but also mitigated mitochondrial dysfunction and dilated cardiomyopathy. Taken together, these findings identify MTORC1 as a novel therapeutic target for BTHS, suggesting that pharmacological restoration of mitophagy may provide a novel treatment for BTHS. BTHS: Barth syndrome; CCCP: carbonyl cyanide 3-chlorophenylhydrazone; CL: cardiolipin; EIF4EBP1/4E-BP1: eukaryotic translation initiation factor 4E binding protein 1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; KD: knockdown; KO: knockout; LAMP1: lysosomal-associated membrane protein 1; LV: left ventricle; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MEFs: mouse embryonic fibroblasts; MTORC1: mechanistic target of rapamycin kinase complex 1; OCR: oxygen consumption rate; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PINK1: PTEN induced putative kinase 1; PRKN/Parkin: parkin RBR E3 ubiquitin protein ligase; qRT-PCR: quantitative real-time polymerase chain reaction; RPS6KB/S6K: ribosomal protein S6 kinase beta; SQSTM1/p62: sequestosome 1; TLCL: tetralinoleoyl cardiolipin; WT: wild-type.

摘要

巴德-希利综合征(Barth syndrome,BTHS)是一种 X 连锁的遗传性疾病,由编码必需的酰基转移酶的基因突变引起,该酶参与心磷脂重塑。心磷脂是一种线粒体特征性磷脂,在心磷脂重塑中发挥关键作用,对维持线粒体膜结构、呼吸、线粒体 DNA 生物发生和线粒体自噬至关重要。基因中的突变导致成熟心磷脂耗竭,导致 BTHS 患者的线粒体功能障碍、扩张型心肌病和过早死亡。目前,这种使人衰弱的疾病还没有有效的治疗方法。在这项研究中,我们发现 TAFAZZIN 缺乏会导致 MTORC1 信号的过度激活和线粒体自噬缺陷,导致心磷脂敲低小鼠(一种巴德-希利综合征的啮齿动物模型)心脏中自噬小泡和功能失调的线粒体堆积。因此,用雷帕霉素(一种有效的 MTORC1 抑制剂)治疗 TAFAZZIN 敲低小鼠不仅恢复了线粒体自噬,而且减轻了线粒体功能障碍和扩张型心肌病。总之,这些发现确定 MTORC1 是 BTHS 的一个新的治疗靶点,提示药理学恢复线粒体自噬可能为 BTHS 提供一种新的治疗方法。BTHS:巴德-希利综合征;CCCP:羰基氰化物 3-氯苯腙;CL:心磷脂;EIF4EBP1/4E-BP1:真核翻译起始因子 4E 结合蛋白 1;GAPDH:甘油醛-3-磷酸脱氢酶;KD:敲低;KO:敲除;LAMP1:溶酶体相关膜蛋白 1;LV:左心室;MAP1LC3/LC3:微管相关蛋白 1 轻链 3;MEFs:小鼠胚胎成纤维细胞;MTORC1:雷帕霉素靶蛋白激酶复合物 1;OCR:耗氧量;PE:磷脂酰乙醇胺;PIK3C3/VPS34:磷脂酰肌醇 3-激酶催化亚单位 3;PINK1:PTEN 诱导的假定激酶 1;PRKN/Parkin:parkin RBR E3 泛素蛋白连接酶;qRT-PCR:实时定量聚合酶链反应;RPS6KB/S6K:核糖体蛋白 S6 激酶 β;SQSTM1/p62:自噬体相关蛋白 1;TLCL:四油酰基心磷脂;WT:野生型。

相似文献

1
Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome.恢复线粒体自噬可改善 Barth 综合征的心肌病。
Autophagy. 2022 Sep;18(9):2134-2149. doi: 10.1080/15548627.2021.2020979. Epub 2022 Jan 5.

引用本文的文献

5
Mitochondrial diseases: from molecular mechanisms to therapeutic advances.线粒体疾病:从分子机制到治疗进展
Signal Transduct Target Ther. 2025 Jan 10;10(1):9. doi: 10.1038/s41392-024-02044-3.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验